Skip to main
  1. Stocks
  2. iRhythm Technologies
  3. Forecast
IRTC

iRhythm Technologies (IRTC) Stock Forecast & Price Target

iRhythm Technologies (IRTC) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 40%
Buy 47%
Hold 13%
Sell 0%
Strong Sell 0%

Bulls say

iRhythm Holdings is attractive because its core Zio franchise continues to deliver durable mid-teens growth while the business demonstrates strong operating leverage, with revenue of $221.6M up 14.9% y/y and adjusted EBITDA of $51.2M at a 23.1% margin, far above expectations. Even with elevated GAAP operating expenses of $197.0M, adjusted opex fell 2.0% y/y and gross margin expanded to 74.2%, showing the underlying model can scale efficiently as manufacturing automation, product mix, and operating discipline improve. Looking ahead, management’s framework for roughly $1.75B of combined 2027 revenue, above 70% gross margin, and at least 15% adjusted EBITDA margin supports the view that VitalConnect broadens the addressable market and strengthens the long-term growth path despite near-term integration noise.

Bears say

iRhythm Holdings is facing a deteriorating fundamental setup because 3Q26 revenue of $221.6M, up 14.9% y/y, still missed consensus while Zio AT was flat and new-account onboarding slowed as customers waited for the combined AT/VitalPatch platform. Management also pushed the Zio MCT FDA submission into 2027, undermining the near-term growth thesis and contributing to lowered organic expectations, with 2026 guidance only partly lifted by $16M of VitalConnect offsetting an $8.5M organic headwind. Beyond execution issues, the company remains burdened by FDA warning-letter scrutiny, 2024 compliance observations, an ongoing DOJ investigation tied to 2017-2022 reimbursement claims, reimbursement pressure, and rising competition, all of which can weigh on confidence and valuation.

iRhythm Technologies (IRTC) has been analyzed by 15 analysts, with a consensus rating of Buy. 40% of analysts recommend a Strong Buy, 47% recommend Buy, 13% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iRhythm Technologies and is not a guaranteed prediction by Public.com or investment advice.

iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction

Get the latest iRhythm Technologies (IRTC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in iRhythm Technologies (IRTC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iRhythm Technologies (IRTC) Forecast

Analysts have given iRhythm Technologies (IRTC) a Buy based on their latest research and market trends.

According to 15 analysts, iRhythm Technologies (IRTC) has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $159.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $159.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iRhythm Technologies (IRTC)


iRhythm Technologies (IRTC) Analyst Forecast & Price Prediction

Get the latest iRhythm Technologies (IRTC) stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in iRhythm Technologies (IRTC)

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover IRTC stock data and trends